Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma (pages 3680–3686)
Guillemette Fouquet, Stéphanie Tardy, Hélène Demarquette, Sarah Bonnet, Julie Gay, Houria Debarri, Charles Herbaux, Stéphanie Guidez, Jessica Michel, Aurore Perrot, Caroline Serrier, Darko Miljkovic, Hervé Avet Loiseau, Thierry Facon, Cyrille Hulin and Xavier Leleu
Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28274
The objective of the current study was to determine the efficacy and safety profile of long-term exposure (≥ 2 years) to the combination of lenalidomide and dexamethasone in 50 patients with recurrent/refractory multiple myeloma (RRMM). The authors report an overall response rate of 96%, which is higher than expected, but that translated into a prolonged time to disease progression of 78% at 37 months, especially in patients exposed to lenalidomide for ≥ 3 years. The authors believe the results of the current study confirm that treatment with lenalidomide in combination with dexamethasone is feasible in the long-term treatment of patients with RRMM. The safety profile of long-term exposure to lenalidomide appears to be manageable, with a significant benefit in terms of time to disease progression noted in these patients.